Antion Biosciences announces development of safety-enhanced and off-the-shelf CAR T-cells for autoimmune disease Aiming for a best-in-class solution to treat and cure B-cell driven autoimmune diseases

Antion Biosciences announces latest data and validation of its technology platform through important milestone achievements Antion Biosciences release in vivo proof-of-concept data for miCAR7 and milestone achievement for Allogene Therapeutics

Antion Biosciences Announces Presentation of Two Abstracts from its Multiplex Cell Engineering Platform at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting Functional demonstration of Antion’s uniquely capable technology to develop allogeneic anti-CD19 CAR T-cells with “tuned” silencing of HLA-I Latest advancements in the application of Antion’s miCAR...